# NY Advances Cannabis Research In First Study On CBD, THC, And IBD > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ny-advances-cannabis-research-in-first-study-on-cbd-thc-and-ibd/ > **Published:** 2026-05-13T17:02:26-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:55:14-04:00 > **Clinical Summary:** First prospective study examines CBD THC inflammatory bowel disease effects. Clinical implications for IBD management reviewed. --- ✦ New CED Clinical Relevance** #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchCBDTHCPolicySafetyAnxietyMental Health Why This Matters This research provides clinicians with evidence-based data on cannabinoid efficacy for IBD patients, potentially offering an alternative or adjunctive therapeutic option for those with inadequate response to conventional treatments. As cannabis remains federally illegal in most contexts, this state-level research helps bridge the knowledge gap between patient use and clinical guidance, enabling providers to counsel patients more effectively on risks and benefits. The findings could inform future clinical practice guidelines and help standardize dosing and cannabinoid ratios for gastrointestinal conditions. Clinical Summary New York has initiated a [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) program examining the effects of cannabidiol (CBD) and tetrahydrocannabinol (THC) on inflammatory bowel disease (IBD) symptoms, representing one of the first systematic studies of cannabis constituents in this patient population. This research addresses a significant gap in the evidence base, as many IBD patients report symptom relief from cannabis use despite limited rigorous clinical data to support efficacy or guide dosing recommendations. The findings are expected to provide clinicians with evidence-based information about cannabinoid efficacy, safety profiles, and optimal cannabinoid ratios for IBD management, potentially informing whether and how to counsel patients on cannabis use as an adjunctive or [alternative therapy](https://cedclinic.com/cannabis-for-chronic-pelvic-pain-self-management/). Currently, most guidance on cannabis for IBD relies on anecdotal reports and mechanistic hypotheses rather than [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), leaving providers uncertain about patient safety and efficacy. Clinicians should remain attentive to emerging data from this study, as positive results could support the development of standardized cannabis-based therapeutics for IBD and help establish clear clinical guidelines for patient selection and monitoring. Dr. Caplan’s Take “We’ve been managing IBD patients with cannabis for years based on symptom reports, but this New York study gives us the rigorous data we’ve needed to understand which cannabinoid ratios actually modulate inflammation versus simply masking pain, which changes how I counsel patients about realistic expectations and dosing strategies.” Clinical Perspective New York’s initiation of formal [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) in inflammatory bowel disease represents an important step toward filling a significant evidence gap, as many IBD patients report using cannabis for symptom management despite limited clinical data. While the study design and preliminary findings remain unpublished, clinicians should recognize that patient interest in cannabinoid therapies—particularly CBD and THC—will likely increase as legitimacy research accumulates, even if efficacy remains unproven. The complexity here involves not only establishing whether these compounds meaningfully improve symptoms or inflammation, but also understanding optimal dosing, long-term safety profiles, and potential drug interactions in a population often managed with immunosuppressants and biologics. Until rigorous results emerge, practitioners can acknowledge patient interest while avoiding endorsement, documenting use patterns, and remaining alert to emerging literature that may eventually inform evidence-based recommendations in IBD care. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20NY%20Advances%20Cannabis%20Research%20In%20First%20Study%20On%20CBD%2C%20THC%2C%20And%20IBD%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52746)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52746)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20NY%20Advances%20Cannabis%20Research%20In%20First%20Study%20On%20CBD%2C%20THC%2C%20And%20IBD%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52746)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [In the Mix: 11 More Articles — May 08, 2026](https://cedclinic.com/cannabis-clinical-relevance-updates-may-2026/) - [CED Digest: 23 Items — April 25, 2026](https://cedclinic.com/cannabis-clinical-updates-april-25-2026/) - DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research** Backed by NFL … – StreetInsider 📰 Source: [https://www.harlemworldmagazine.com/ny-advances-cannabis-research-in-first-study-on-cbd-thc-and-ibd/](https://www.harlemworldmagazine.com/ny-advances-cannabis-research-in-first-study-on-cbd-thc-and-ibd/) Further Reading Cannabis Policy Wire[Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) CED Clinic Blog[Fear of recurrence, secondary cancers, and health problems in long-term survivors of childhood cancer: Findings from a Canadian cohort.](https://cedclinic.com/fear-of-recurrence-secondary-cancers-and-health-problems-in-long-term-survi/) CED Clinic Blog[Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical cannabis patients across 45 days.](https://cedclinic.com/associations-of-cannabis-use-other-substances-and-lifestyle-choices-on-anxi/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).